Evidence map›Paper›PMID 40558899›Full record

ReviewJournal of functional biomaterials2025

Material-Driven Therapeutics: Functional Nanomaterial Design Paradigms Revolutionizing Osteosarcoma Treatment.

Zewei Zhang, Fang He, Wenqu Li, Beibei Liu, Cheng Deng, Xiaojuan Qin

Abstract readReview
In one paragraph

Review in Journal of functional biomaterials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zewei ZhangDepartment of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Fang HeDepartment of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Wenqu LiDepartment of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Beibei LiuDepartment of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Cheng DengDepartment of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Xiaojuan QinDepartment of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.ORCID 0000-0002-0113-169X

Funding

the Key Research and Development Program of Hubei Nos. 2022BCA050the National Natural Science Foundation of China 82200648the Nature Science Foundation of Hubei Province 2024AFB032the Open Research Fund of Hubei Province Key Laboratory of Precision Radiation Oncology No. 2024ZLJZFL010
6 · The paper itself

Abstract

Osteosarcoma (OS), a prevalent primary malignant bone tumor in children and adolescents, has maintained consistent treatment protocols since the 1970s combining surgery, chemotherapy, and radiotherapy. While effective for localized tumors, these strategies show limited efficacy against metastatic or recurrent cases. Although emerging immunotherapies (PD-1 inhibitors, CAR-T-cell therapy) demonstrate therapeutic potential, their clinical impact remains constrained by the tumor's low immunogenicity and immunosuppressive microenvironment, resulting in suboptimal response rates. The disease's aggressive nature and propensity for pulmonary metastasis contribute to poor prognosis, with survival rates showing negligible improvement over five decades despite therapeutic advances, creating substantial clinical and socioeconomic challenges. Recent developments in nanomedicine offer promising solutions for OS treatment optimization. This review systematically examines nanomaterial applications in OS therapy through a materials science lens, analyzing mechanism-specific interventions and highlighting notable advancements from the past five years. We critically evaluate current strategies for enhancing therapeutic efficacy while reducing toxicity profiles, ultimately outlining translational pathways and key challenges in clinical adaptation. The analysis establishes a framework for developing next-generation nanotherapeutic platforms to address persistent limitations in OS management.

Indexed as

malignant bone tumornanomaterialsosteosarcomatreatment

Identifiers

PMID40558899
PMCPMC12194080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.